Portable Truenat-based PCR testing supports rapid detection of Ebola disease caused by Bundibugyo viruses
On 17 May, the World Health Organization declared the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda a Public Health Emergency of International Concern. As of 21 May, 746 suspected cases and 176 deaths among suspected cases had been reported in the DRC. Across both countries, 85 confirmed cases, including 2 in Uganda, and 10 deaths among confirmed cases, including 1 in Uganda, had been reported.
The current outbreak is linked to the Bundibugyo virus. Along with the Ebola virus and Sudan virus, it is one of three viruses known to cause large outbreaks of Ebola disease.
On 22 May, Molbio Diagnostics participated in the emergency consultation convened by the World Health Organization and the Africa Centres for Disease Control and Prevention (Africa CDC), bringing together key stakeholders to accelerate the research, development, and deployment of decentralised diagnostic solutions to support outbreak response efforts. The consultation highlighted significant challenges arising from the limited availability of appropriate decentralised testing solutions for the disease caused by the Bundibugyo virus.
Molbio has developed a real-time PCR test capable of detecting Ebola disease caused by all three outbreak-associated viruses — Ebola virus, Sudan virus, and Bundibugyo virus. Designed for decentralised settings, the test runs on Molbio’s near-patient portable Truenat platform and delivers results in approximately one hour, enabling faster clinical decision-making and timely public health intervention.
Molbio is currently working closely with the World Health Organization, the Africa Centres for Disease Control and Prevention, and local authorities to validate the test on clinical specimens urgently. Initial deployment has commenced, and test kits have already reached affected regions in Uganda and the DRC.
Molbio remains committed to supporting public health authorities and global health agencies in strengthening outbreak preparedness and response through accessible molecular diagnostics.
About Molbio Diagnostics Limited:
Molbio Diagnostics Limited is an innovative point-of-care diagnostics company. With a commitment to providing rapid, accurate, and cost-effective diagnostic solutions, Molbio brings advanced healthcare technologies to the remotest areas. The company’s flagship Truenat®️ real-time PCR platform is globally recognized and endorsed by the World Health Organization (WHO), enhancing infectious disease management worldwide. Molbio is dedicated to improving healthcare accessibility and quality with innovative diagnostics that meet global standards.
For further queries, please contact:
Runjun Dutta
Email: runjun.dutta@molbiodiagnostics.com
Ph: +91 9871800723
DISCLAIMER:
Molbio Diagnostics Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus (“DRHP”) with Securities and Exchange Board of India (“SEBI”) with the Registrar of Companies, Goa, Daman and Diu at Panaji. The DRHP is available on the website of the Company at www.molbiodiagnostics.com/investors, the website of the SEBI at www.sebi.gov.in, as well as on the websites of the book running lead managers, Kotak Mahindra Capital Company Limited at www.investmentbank.kotak.com, IIFL Securities Limited at www.iiflcap.com, Jefferies India Private Limited at www.jefferies.com and Motilal Oswal Investment Advisors Limited at www.motilaloswalgroup.com, and the websites of the stock exchange(s) at www.nseindia.com and www.bseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see “Risk Factors” of the RHP, when available. Potential investors should not rely on the DRHP for any investment decision.
The Equity Shares have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in “offshore transactions” as defined in and in reliance on, Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.